Concord Biotech stock gains 3% as Kotak and Antique Broking issue positive coverage
Kotak Institutional Equities based on strong discounted cash flows and the company's expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment sees a 15 percent upside potential from the current price levels.22-09-2023